292 related articles for article (PubMed ID: 34626666)
1. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.
Senkevich K; Rudakou U; Gan-Or Z
Neuropharmacology; 2022 Jan; 202():108822. PubMed ID: 34626666
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
von Linstow CU; Gan-Or Z; Brundin P
Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
[TBL] [Abstract][Full Text] [Related]
3. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.
Schneider SA; Alcalay RN
J Neurol; 2020 Mar; 267(3):860-869. PubMed ID: 31974807
[TBL] [Abstract][Full Text] [Related]
6. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
[TBL] [Abstract][Full Text] [Related]
7. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations.
Mangone G; Bekadar S; Cormier-Dequaire F; Tahiri K; Welaratne A; Czernecki V; Pineau F; Karachi C; Castrioto A; Durif F; Tranchant C; Devos D; Thobois S; Meissner WG; Navarro MS; Cornu P; Lesage S; Brice A; Welter ML; Corvol JC;
Parkinsonism Relat Disord; 2020 Jul; 76():56-62. PubMed ID: 32866938
[TBL] [Abstract][Full Text] [Related]
8. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
[TBL] [Abstract][Full Text] [Related]
9. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
[TBL] [Abstract][Full Text] [Related]
10. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
11. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.
Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Shenhar-Tsarfaty S; Mirelman A
J Neurol; 2021 Apr; 268(4):1517-1525. PubMed ID: 33388928
[TBL] [Abstract][Full Text] [Related]
13. Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.
Shani S; Goldstein O; Gana-Weisz M; Bar-Shira A; Thaler A; Gurevich T; Mirelman A; Giladi N; Alcalay RN; Orr-Urtreger A
Parkinsonism Relat Disord; 2023 Jun; 111():105398. PubMed ID: 37116292
[TBL] [Abstract][Full Text] [Related]
14. Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.
Huang J; Cheng Y; Li C; Shang H
Transl Neurodegener; 2022 Apr; 11(1):21. PubMed ID: 35395825
[TBL] [Abstract][Full Text] [Related]
15. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.
Alcalay RN; Mejia-Santana H; Tang MX; Rakitin B; Rosado L; Ross B; Verbitsky M; Kisselev S; Louis ED; Comella CL; Colcher A; Jennings D; Nance MA; Bressman S; Scott WK; Tanner C; Mickel SF; Andrews HF; Waters CH; Fahn S; Cote LJ; Frucht SJ; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Ottman R; Clark LN; Marder KS; Caccappolo E
J Clin Exp Neuropsychol; 2010 Aug; 32(7):775-9. PubMed ID: 20182943
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
[TBL] [Abstract][Full Text] [Related]
17. Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2/GBA mutated Parkinson's disease.
Lin F; Ruan X; Zou X; Weng H; Zeng Y; Zheng J; Ye Q; Meng F; Chen X; Cai G
CNS Neurosci Ther; 2024 Jun; 30(6):e14728. PubMed ID: 38837664
[TBL] [Abstract][Full Text] [Related]
18. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
19. Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease.
Halder T; Verma SP; Raj J; Pandey S; Singh RK; Sharma V; Joshi D; Das P
Indian J Med Res; 2020 Nov; 152(5):498-507. PubMed ID: 33707392
[TBL] [Abstract][Full Text] [Related]
20. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
